Scinovex
review Open AccessTop 1% cited

Regulated cell death pathways in doxorubicin-induced cardiotoxicity

Cell Death and Disease · 2021 · Vol. 12(4) · pp. 339–339
Effimia ChristidiLiam R. Brunham

Abstract

Doxorubicin is a chemotherapeutic drug used for the treatment of various malignancies; however, patients can experience cardiotoxic effects and this has limited the use of this potent drug. The mechanisms by which doxorubicin kills cardiomyocytes has been elusive and despite extensive research the exact mechanisms remain unknown. This review focuses on recent advances in our understanding of doxorubicin induced regulated cardiomyocyte death pathways including autophagy, ferroptosis, necroptosis, pyroptosis and apoptosis. Understanding the mechanisms by which doxorubicin leads to cardiomyocyte death may help identify novel therapeutic agents and lead to more targeted approaches to cardiotoxicity testing.

Chemotherapy-induced cardiotoxicity and mitigationPeptidase Inhibition and AnalysisInflammasome and immune disordersNecroptosisCardiotoxicityDoxorubicinPyroptosisAutophagyProgrammed cell deathApoptosisCancer researchPharmacologyMedicine

MeSH terms

NecroptosisAnimalsAutophagyDoxorubicinHumansApoptosisMyocytes, CardiacCardiotoxicity

Funding

  • Michael Smith Health Research BC
  • Canadian Institutes of Health Research
Citations
626
FWCI
67.64
field-weighted impact
References
138
Percentile
100%
vs. same field & year
Citations per year
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.